DaVita (DVA) Stock
Key stats
- Market cap
- $11.46B
- Price / Earnings ratio
- 12.5x
- EPS (TTM)
- $13.81
- Volume
- Loading
- 52-week high
- $247.49
- 52-week low
- $101.00
- EPS vs analyst estimate
- -22.0%Q3 FY25 · $2.51 vs $3.22
Source: third-party data provider, as of November 5, 2026
EPS estimate: analyst consensus
Compare with DVA
Recent news

Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.
Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.
DVA

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
DVA

What DaVita (DVA) Said on Its Q3 Earnings Call
What DaVita (DVA) Said on Its Q3 Earnings Call
DVA

DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
DVA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 58.18
- MACD 12/26/9
- 1.55
- EMA 9 of MACD
- 0.80
- MACD histogram
- 0.75
- SMA 50
- $182.05
- Price above SMA 50
- EMA 50
- $185.35
- Price above EMA 50
- SMA 200
- $178.24
- Price above SMA 200
- EMA 200
- $169.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.33 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.
Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.
DVA

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
DVA

What DaVita (DVA) Said on Its Q3 Earnings Call
What DaVita (DVA) Said on Its Q3 Earnings Call
DVA

DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
DVA

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
DVA

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know
DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know
DVA

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
DVA

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
DVA

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA

3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs
3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs
DVA
News tone: automated (AI) classification of the article's content, not a price prediction.
About DaVita
DaVita is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients around the globe. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Javier J. Rodriguez | CEO & Executive Director | 1971 |
| Mr. Joel Ackerman | CFO & Treasurer | 1965 |
| Mr. David P. Maughan | Chief Operating Officer of DaVita Kidney Care | 1977 |
| Ms. Kathleen Alyce Waters | Chief Legal & Public Affairs Officer | 1968 |
| Mr. James O. Hearty | Chief Compliance Officer | 1969 |
| Mr. Christopher Michael Berry CPA | Group VP & Chief Accounting Officer | 1975 |
| Nic Eliason | Group Vice President of Investor Relations | — |
| Ms. Stephanie Hendrickson | Chief People Officer | — |
| Mr. Misha Palecek | Chief Transformation Officer of U.S. Kidney Care Business | — |
| Dr. Jeffrey Allen Giullian | Chief Medical Officer of Kidney Care | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 5, 2026
Technical indicators
- RSI 14
- 58.18
- MACD 12/26/9
- 1.55
- EMA 9 of MACD
- 0.80
- MACD histogram
- 0.75
- SMA 50
- $182.05
- Price above SMA 50
- EMA 50
- $185.35
- Price above EMA 50
- SMA 200
- $178.24
- Price above SMA 200
- EMA 200
- $169.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $215.00
- Average
- $236.50
- High
- $287.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.6 | +20.1 | ||||||||||
| 2022 | -6.1 | +3.4 | +1.9 | -5.1 | -9.1 | -16.2 | +1.3 | +0.5 | -4.8 | -15.5 | +5.5 | +2.0 |
| 2023 | +10.1 | -3.0 | -1.5 | +10.6 | +3.6 | +6.1 | +1.2 | +0.0 | -8.2 | -18.8 | +31.0 | +0.4 |
| 2024 | +1.2 | +13.1 | +8.8 | +0.8 | +5.3 | -4.8 | -1.4 | +9.7 | +7.9 | -14.1 | +17.4 | -8.7 |
| 2025 | +17.6 | -16.5 | +6.9 | -6.8 | -3.0 | +6.0 | -4.3 | -0.5 | -3.0 | -10.4 | +0.5 | -4.7 |
| 2026 | -4.5 | +40.6 | -0.2 | +3.2 | +28.2 | +17.2 | +5.3 | -24.7 | -0.7 | +6.3 | +3.7 |



